Omar SA, Attia NM, Sheir MI, et al. - In this analytic-prospective study, researchers sought to assess the serum endocan level as a prognostic biomarker for recurrence of hepatocellular cancer (HCC) after percutaneous radiofrequency ablation. This investigation was performed in Suez Canal University Hospitals. Eighty patients were divided into three groups: group 1 (control group) consisted of 20 apparently healthy persons; group 2 consisted of 20 patients with liver cirrhosis; group 3 consisted of 40 treatment-naive HCC patients who were ready for radiofrequency ablation. The study found that the HCC group had a high level of serum endocan, with a statistically significant difference between the three groups. Serum endocan is thought to be a prognostic biomarker for tumor recurrence in HCC patients after radiofrequency ablation.